Halozyme Therapeutics (HALO) Tops Q1 EPS by 6c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $113.34 -1.55%
EPS Growth %: +30.8%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +30.8%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $1.60, $0.06 better than the analyst estimate of $1.54. Revenue for the quarter came in at $377 million versus the consensus estimate of $358.45 million.
GUIDANCE:
Halozyme Therapeutics sees FY2026 EPS of $7.75-$8.25, versus the consensus of $8.09. Halozyme Therapeutics sees FY2026 revenue of $1.71-1.81 billion, versus the consensus of $1.76 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paramount Weighs Tapping Musk For Equity Investment - Semafor
- DelphX closes C$61,000 non-brokered private placement
- US Treasury To Buy Back Up To $6B In Longer-dated Debt Thu. - Bloomberg
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
